Last reviewed · How we verify
NCT06734533
Anlotinib-based Combination Therapy in Patients with Hormone Receptor-positive（HR+） Metastatic Breast Cancer(MBC) .
trial testing Anlotinib+eribulin/nab-paclitaxel/etoposide/capecitabine/pembrolizumab/ sintilimab/ fulvestrant, etc in HR+ Breast Cancer in 80 participants. Currently enrolling.
1 December 2025
Quick facts
| Lead sponsor | Hunan Cancer Hospital |
|---|---|
| Status | Recruiting now |
| Study type | OBSERVATIONAL |
| Enrollment | 80 |
| Start date | 5 December 2024 |
| Primary completion | 1 December 2025 |
| Estimated completion | 30 December 2025 |
| Sites | 1 location across China |
Drugs / interventions tested
- Anlotinib+eribulin/nab-paclitaxel/etoposide/capecitabine/pembrolizumab/ sintilimab/ fulvestrant, etc
Conditions studied
- HR+ Breast Cancer — all drugs for HR+ Breast Cancer →
Sponsor
Hunan Cancer Hospital
Who can join
Adults 18 to 75, female only, with HR+ Breast Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Cyclin-dependent kinases 4 and 6 (CDK4/6) inhibitors combined with hormonal therapy are the current standard frontline treatment for patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2 (HER-2)-negative metastatic breast cancer (MBC). However, the optimal treatment after progression on CDK4/6 inhibitors remains unknown. Anlotinib is an oral multi-target tyrosine kinase inhibitor (TKI) that strongly inhibits VEGFR, PDGFR, FGFR, and c-kit. This study aimed to evaluate the safety and efficacy of anlotinib-based combination therapy in patients with HR+ MBC previously treated with a CDK4/6 inhibitor.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06734533
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for HR+ Breast Cancer
Currently open trials in the same condition.
- NCT07029399 — A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors · Phase 1 · recruiting
Other Hunan Cancer Hospital trials
Trials by the same sponsor.
- NCT07314216 — Firmonertinib Combined With Definitive Radiotherapy in Stage III Unresectable EGFR Uncommon Mutant Pulmonary Adenocarcin · Phase 2 · not yet recruiting
- NCT07083687 — Lorlatinib in ROS1+ NSCLC With Brain Metastasis · Phase 2 · not yet recruiting
- NCT07098026 — Shenqi Fuwei Mixture Combined With Chemotherapy Neoadjuvant Therapy for Locally Advanced Gastric Cancer · NA · recruiting
- NCT06840704 — Immunonutrition Reduces Acute Esophagitis After Thoracic Radiotherapy in Lung Cancer · Phase 3 · recruiting
- NCT06788002 — LDRT and Chemoimmunotherapy in NPC With Liver Metastasis · Phase 2 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06734533 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Hunan Cancer Hospital
- Last refreshed: 16 December 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06734533.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing